Skip to main content
Article thumbnail
Location of Repository

Sero-epidemiology of rubella in the urban population of Addis Ababa Ethiopia

By Felicity Cutts, A. Abebe, T. Messele, A. Dejene, F. Enquselassie, Wondatir Nigatu and D. James Nokes


We conducted a community-based cluster sample survey of rubella sero-epidemiology in Addis Ababa, Ethiopia in 1994. Among 4666 individuals for whom complete data were available, rubella antibody prevalence was 91% (95% confidence interval: 90, 92). On multivariable analysis, seroprevalence was lower among individuals who were resident in Addis Ababa for 1 year or less. Approx. 50% seroprevalence was attained by age 4 years, and the estimated average age at infection was 5·2 years. The highest age-specific force of infection was estimated to occur in 5- to 9-year-olds. The early age at infection corresponded with a low estimated incidence of congenital rubella syndrome (CRS) of 0·3 per 1000 live births, equivalent to nine cases of CRS in 1994. The predicted critical level of immunity for elimination of rubella via vaccination was 85–91%, requiring 89–96% coverage with a vaccine of 95% effectiveness. Unless very high coverage of rubella vaccine could be guaranteed, the introduction of childhood vaccination could increase the incidence of CRS in Addis Ababa

Topics: RA0421
Publisher: Cambridge University Press
Year: 2000
OAI identifier:

Suggested articles


  1. (1974). A catalytic model of infection for measles. Appl Stat doi
  2. (1998). A comparison of oral ¯uid and serum for the detection of rubella-speci®c antibodies in a community study in Addis Ababa, Ethiopia. Trop Med Internat Hlth doi
  3. (1994). A model-based design of a vaccination strategy against rubella in a non-immunized community of Sao Paulo state, Brazil. Epidemiol Infect doi
  4. (1991). A simpli®ed general method for cluster-sample surveys of health in developing countries. World Health Statist Q
  5. (1998). Age- and sexspeci®c
  6. (1982). Consequences of con®rmed maternal rubella at successive stages of pregnancy. Lancet doi
  7. (1997). Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 1: burden of disease from CRS. Bull WHO
  8. (1997). Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 2: vaccination against rubella. Bull WHO
  9. (1993). Herd immunity: history, theory, practice. Epidemiol Rev
  10. (1981). How well do low levels of rubella antibody protect? Lancet doi
  11. (1992). Infectious diseases of humans: dynamics and control.
  12. (1992). La seroepidemiologia de la rubeola en Mexico: datos y teoria. Salud Publ Mex
  13. (1988). Measles in developing countries. Part I. Epidemiological parameters and patterns. Epidemiol Infect doi
  14. (1992). Methods for estimating the incidence of primary infection in pregnancy: a reappraisal of toxoplasmosis and cytomegalovirus data. Epidemiol Infect doi
  15. (1985). Methods of assessing the impact of congenital rubella infection. Rev Infect Dis doi
  16. (1990). Modelling forces of infection for measles, mumps and rubella. Stat Med doi
  17. (1999). Modelling the incidence of congenital rubella syndrome in developing countries. doi
  18. (1992). Modelling toxoplasma incidence from longitudinal seroprevalence in pregnant women doi
  19. (1992). Modelling vaccination programmes. Rev Med Virol
  20. (1994). Population Housing Census Commission. The doi
  21. (1998). Rational use of rubella vaccine for prevention of congenital rubella syndrome in the Americas. doi
  22. (1996). Rubella immunity: de®ning the level of protective antibody.
  23. (1994). Rubella seroepidemiology in a non-immunized population of Sao Paulo State, Brazil. Epidemiol Infect doi
  24. (1993). Rubella Vaccination and congenital rubella syndrome in western Australia. doi
  25. (1979). Rubella vaccines and the immunity gap. Lancet doi
  26. (1985). Sero-epidemiology of rubella in Imo state of Nigeria. Trans Roy Soc Trop Med Hyg doi
  27. (1993). Statistical models in epidemiology. doi
  28. (1988). Surveillance of antibody to measles, mumps, and rubella by age. doi
  29. (1999). The eradication of rubella. JAMA doi
  30. (1985). The estimation of agerelated rates of infection from case noti®cations and serological data.
  31. (1984). The force of measles infection in East Africa. doi
  32. (1983). Vaccination against rubella and measles: quantitative investigations of different policies. doi
  33. (1970). WHO collaborative study on the sero-epidemiology of rubella in Caribbean and middle and south American populations in 1968. Bull WHO

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.